Abstract: SA-PO0603
Elevated IL-37 as a Biomarker for Disease Severity and Prognosis in ADPKD
Session Information
- Cystic Kidney Diseases: Clinical Research
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Genetic Diseases of the Kidneys
- 1201 Genetic Diseases of the Kidneys: Monogenic Kidney Diseases
Authors
- Xue, Cheng, Shanghai Changzheng Hospital, Shanghai, China
- Dong, Zheng, Augusta University, Augusta, Georgia, United States
- Mao, Zhiguo, Shanghai Changzheng Hospital, Shanghai, China
Background
ADPKD involves progressive cyst formation and chronic inflammation. This study aimed to explore interleukin-37 (IL37) expression in ADPKD and evaluate its value in assessing disease severity and prognosis.
Methods
IL37 levels were measured in renal tissues, cyst fluid, serum, and urine from ADPKD patients using PCR, Western blot, immunofluorescence, and ELISA. Correlations with kidney injury markers (NGAL, KIM-1, MCP-1, L-FABP, α1-MG) and renal function were assessed. Kaplan–Meier and Cox regression analyses evaluated the prognostic significance of IL37.
Results
IL37 expression was elevated in ADPKD kidney tissue at both mRNA and protein levels. Immunofluorescence confirmed enhanced IL37 localization. ELISA showed significantly higher IL37 levels in cyst fluid, serum, and urine in ADPKD vs. controls. Urinary IL37/uCr increased with CKD stage and correlated positively with NGAL, L-FABP, MCP-1, α1-MG, and inversely with eGFR. Patients with higher serum or urine IL37 had worse renal survival. In multivariate Cox models, both serum (HR=2.124, P=0.023) and urinary IL37/uCr (HR=2.143, P<0.001) independently predicted ESKD progression.
Conclusion
IL37 is upregulated in ADPKD tissues and biofluids, correlates with kidney injury markers, and independently predicts disease progression in ADPKD.
Funding
- Government Support – Non-U.S.